We are live on ! Find out more
SPRO icon

Spero Therapeutics

50 hedge funds and large institutions have $143M invested in Spero Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

734% more capital invested

Capital invested by funds: $17.2M → $143M (+$126M)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

0.78% less ownership

Funds ownership: 26.91%26.13% (-0.78%)

7% less funds holding

Funds holding: 5450 (-4)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $29K

Holders
50
Holders Change
-4
Holders Change %
-7.41%
% of All Funds
0.73%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
6
Increased
10
Reduced
10
Closed
8
Calls
Puts
$29K
Net Calls
-$29K
Net Calls Change
+$44K
Name Holding Trade Value Shares
Change
Change in
Stake
HF
51
HRT Financial
New York
-$22K -18,627 Closed
Two Sigma Investments
52
Two Sigma Investments
New York
-$20.6K -17,023 Closed
EFL
53
ERn Financial LLC
Wisconsin
-$19.1K -15,766 Closed
WWP
54
WR Wealth Planners
Missouri
-$3.15K -2,600 Closed
CFB
55
Cullen/Frost Bankers
Texas
-$2.42K -2,000 Closed
BHWM
56
Beaird Harris Wealth Management
Texas
-$245 -202 Closed
HWA
57
Heritage Wealth Advisors
Virginia
-$226 -187 Closed
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
+$18 +15 +5%

SPRO Hedge Fund Activity: Q4 2023 in Review

50 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2023, worth a combined $143M — up 734% from $17.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SPRO and 6 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 10 added.

The largest buyer was Anson Funds Management, adding an estimated $165K. The largest seller was Ameriprise, cutting an estimated $72.3K.

  • 50 institutional investors held Spero Therapeutics (SPRO) as of Q4 2023, down from 54 in Q3 2023.
  • Funds reported $143M of Spero Therapeutics stock for Q4 2023, up 734% quarter-over-quarter.
  • 6 funds opened new Spero Therapeutics positions in Q4 2023 and 8 closed out, a net change of -2 holders.
  • The largest Spero Therapeutics buyer in Q4 2023 was Anson Funds Management, an estimated $165K added.
  • The largest Spero Therapeutics seller in Q4 2023 was Ameriprise, an estimated $72.3K sold.

Based on aggregated 13F filings for Q4 2023.